icon-folder.gif   Conference Reports for NATAP  
 
  18th International Workshop on
Clinical Pharmacology of Antiviral Therapy
June 14-17, 2017
Chicago, Ill.C
Back grey_arrow_rt.gif
 
 
 
The Effect of Hepatic or Renal Impairment on Bictegravir Pharmacokinetics
 
 
  Download the PDF here
 
Reported by Jules Levin
18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-16, 2017, Chicago, IL
 
Heather Zhang, Yongwu Shao, Will Garner, Amanda Vu, Hal Martin, Devi SenGupta, Erin Quirk, Brian P. Kearney, Joseph M. Custodio
Gilead Sciences, Inc., Foster City, California, USA
 
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment - (06/13/17) 
 
CROI: Randomized Trial of Bictegravir or Dolutegravir with FTC/TAF for Initial HIV Therapy
- (02/16/17)

0621171

0621172

0621173

0621174

0621175